Oregon Public Employees Retirement Fund Has $1.81 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Oregon Public Employees Retirement Fund decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,092 shares of the medical equipment provider’s stock after selling 380 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Zimmer Biomet were worth $1,805,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Roman Butler Fullerton & Co. acquired a new position in Zimmer Biomet during the fourth quarter worth $473,000. Geode Capital Management LLC raised its holdings in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the last quarter. M&T Bank Corp grew its stake in shares of Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after acquiring an additional 8,709 shares in the last quarter. KLCM Advisors Inc. bought a new stake in shares of Zimmer Biomet in the 4th quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth $654,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZBH. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Raymond James reduced their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $104.32 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $20.77 billion, a PE ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a 50-day moving average price of $105.72 and a two-hundred day moving average price of $107.38.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 earnings per share. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.